Canaccord raised the firm’s price target on Taysha Gene Therapies (TSHA) to $8 from $6 and keeps a Buy rating on the shares. The firm said its thinking on the competitive dynamic for Rhett Syndrome has not changed following its Q4 report and they updated its model and target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA: